Aspen FY26 normalised headline EPS rises 22% to 801.5 cents; revenue slips 1% to R 34.87 billion

• Aspen Pharmacare reported profit attributable to equity holders of ZAR 2.65 billion, swinging from a loss a year earlier.
• Headline earnings per share fell 20% to 630 cents; earnings per share turned positive at 596 cents.
• Continuing-operations operating profit returned to profit at ZAR 763 million; revenue slipped 1% to ZAR 34.87 billion.
• Net cash reached about ZAR 0.8 billion after the APAC divestment, with gross proceeds of ZAR 28 billion and ZAR 0.5 billion buybacks.
• A gross dividend of 232 cents a share was declared, up 10%, with payment set for Oct. 12.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspen Pharmacare Holdings Ltd. published the original content used to generate this news brief on September 01, 2026, and is solely responsible for the information contained therein.